Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

LONDON, October 12, 2011 /PRNewswire/ --

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

"Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012.  Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.

ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments and also does not carry the risk of hypersensitivity reactions as is the case with currently marketed intravenous iron therapies.  Whilst prescribers often try oral ferrous products as first line therapy, many subjects prove intolerant and suffer from continuously occurring side effects, exacerbation of inflammatory lesions and failure to correct iron deficiency.  This results in the need for expensive, complicated and invasive intravenous iron therapy.  When treated with ST10, the total dose exposure of unabsorbed iron within the gastrointestinal tr
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics ... from a new partner. STT-Systems has developed an ... years, with offerings in the optical-motion capture, 3D scanning, and ... measurement unit), iSen, is opening eyes around the world. With ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... world,s first commercially achieved F.O.G. (fats, oils, grease) wastewater treatment ... Laguna Beach. , ... San Marcos, ... Reduction Systems, Inc __title__ Green Technology for the Hospitality Industry] ...
... Aug. 6 deCODE genetics,(Nasdaq: DCGN ) ... ended June 30, 2008. A conference call to ... be webcast live tomorrow,Thursday, August 7, at 8:00am ... Operating loss for the second quarter 2008 was ...
... California venture will use personalized stem cell technology to battle ... ... VIEW, Calif., Aug. 6 iZumi Bio, Inc.,announced today that John ... Stem Cells Generated from Patients with,ALS Can Be Differentiated into Motor ...
Cached Biology Technology:Grease Reduction System a Break Through in Truly "Green" Technology for Luxury Resort 2Grease Reduction System a Break Through in Truly "Green" Technology for Luxury Resort 3deCODE genetics Announces Second Quarter 2008 Financial Results 2deCODE genetics Announces Second Quarter 2008 Financial Results 3deCODE genetics Announces Second Quarter 2008 Financial Results 4deCODE genetics Announces Second Quarter 2008 Financial Results 5deCODE genetics Announces Second Quarter 2008 Financial Results 6deCODE genetics Announces Second Quarter 2008 Financial Results 7deCODE genetics Announces Second Quarter 2008 Financial Results 8deCODE genetics Announces Second Quarter 2008 Financial Results 9iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits 2
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market ... it is important to upgrade biometric solutions to the ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global leader ... series of digital telemetry implants to meet the ... part of the PhysioTel™ Digital platform, was designed ... data when incorporating functional endpoints into repeat-dose toxicology ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... After every meal, the body must prevent the immune ... researchers report the identity of a nutrient "floodgate" that ... Their findings appear in the May 4, 2007 issue ... , The researchers found that animals lacking a protein ...
... body appears to control whether certain medications, such as ... or in inhalers for asthma, lose their effectiveness over ... the body that controls many functions, including the contraction ... conducted by Duke University Medical Center and Howard Hughes ...
... diabetic patients of the superbug MRSA - by treating ... and his team used green bottle fly larvae to ... with MRSA and found all but one were cured ... than the 28-week duration for the conventional treatment. ...
Cached Biology News:Keeping the immune system from starting a 'food fight' 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3Maggots rid patients of MRSA 2
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
... The RapidStak is a fast and ... class. Its high capacity and ... more confident walk away time than ... ease of set-up make for a ...
The Wellwash 4 Mk 2 combines high performance and flexibility with reliability, simplicity and ease of use. This advanced microplate washer meets the exacting standards of today's assay requirements....
Biology Products: